在阿尔茨海默氏症患者中,铁和向铁疗法
Jian Wang1, Jiaying Fu1, Yuanxin Zhao1
1Key Laboratory of Pathobiology, Department of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, China.
International journal of molecular sciences
|November 25, 2023
概括
大脑中铁的积累与阿尔茨海默病 (AD) 的进展有关. 准大脑铁可能为这种常见的神经退行性疾病提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是全球神经退行的主要原因.
- 阿尔茨海默病的关键病理特征包括β-粉样质斑块,高酸化的,以及大脑能量代谢中断.
- 在AD大脑中的异常铁积累与疾病严重程度相关.
研究的目的:
- 审查铁在阿尔茨海默氏症病原发生中的作用.
- 探索铁在氧化应激和能量代谢中的作用.
- 讨论针对AD的铁向治疗策略.
主要方法:
- 关于阿尔茨海默病中铁代谢研究的文献综述.
- 对将铁与氧化应激联系起来的机制的分析 (依赖和独立).
- 评估证据,以铁诱导的能量代谢失调作为阿尔茨海默病的起始因素.
主要成果:
- 铁的积累有助于AD大脑中的氧化应激.
- 铁对能量代谢的调节失调被假设为早期AD触发因素.
- 铁的多方面的作用影响关键的AD病理.
结论:
- 了解铁在阿尔茨海默病中的作用对于开发有效治疗方法至关重要.
- 针对大脑铁的向为阿尔茨海默病提供了一个有前途的治疗途径.
- 对铁介导通路的进一步研究可能会揭示新的AD干预措施.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128


